Comparative Pharmacology
Head-to-head clinical analysis: ATAZANAVIR SULFATE versus DARUNAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATAZANAVIR SULFATE versus DARUNAVIR.
ATAZANAVIR SULFATE vs DARUNAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atazanavir is an azapeptide HIV-1 protease inhibitor. It selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, preventing formation of mature virions.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits the cleavage of HIV-1 encoded Gag-Pol polyproteins in virus-infected cells, thereby preventing formation of mature infectious virions.
300 mg orally once daily with ritonavir 100 mg orally once daily, or 400 mg orally once daily without ritonavir (when used alone).
600 mg orally twice daily with ritonavir 100 mg twice daily or 800 mg orally once daily with cobicistat 150 mg once daily, taken with food.
None Documented
None Documented
Clinical Note
moderateDarunavir + Tenofovir disoproxil
"The serum concentration of Tenofovir disoproxil can be increased when it is combined with Darunavir."
Clinical Note
moderateDarunavir + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Darunavir."
Clinical Note
moderateDarunavir + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Darunavir."
Clinical Note
moderateDarunavir + Clotrimazole
Terminal elimination half-life: ~6.5 to 7 hours; supports once-daily dosing.
Terminal elimination half-life is approximately 15 hours when co-administered with low-dose ritonavir, supporting once-daily dosing.
Biliary/fecal: ~79% as unchanged drug; renal: ~13% (including <1% unchanged).
Primarily fecal (79.5% as unchanged drug or metabolites), with renal excretion accounting for approximately 13.9% (8.9% unchanged).
Category C
Category A/B
Protease Inhibitor
Protease Inhibitor
"The metabolism of Clotrimazole can be decreased when combined with Darunavir."